NBTX vs SNY
Nanobiotix S.a. and Sanofi, side by side — 8 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NBTX | SNY |
|---|---|---|
| Revenue | €32.6M | €43.6B |
| Net income | €-24.0M | €7.8B |
| Gross margin | — | 77.2% |
| Net margin | −73.5% | 17.9% |
| Return on equity | — | 10.5% |
| Diluted EPS | −€0.50 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | — | 61.1% |
| Free cash flow | €-34.0M | — |
| Equity | — | €71.4B |
| Net debt / equity | — | 0.15× |
| Current ratio | 1.09× | 1.09× |
| Revenue CAGR 5y | 67.0% | 3.9% |
| Profit CAGR 5y | — | −8.7% |
SNY bills 1338.5× the revenue of NBTX, and NBTX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
8 years side by side
| Fiscal year | NBTX | SNY |
|---|---|---|
| FY2025 | €32.6M | €43.6B |
| FY2024 | €-7.2M | €41.1B |
| FY2023 | €36.2M | €37.8B |
| FY2022 | €4.8M | €37.7B |
| FY2021 | €2.6M | €37.8B |
| FY2020 | €2.5M | €36.0B |
| FY2019 | €2.5M | €36.1B |
| FY2018 | €3.5M | €34.5B |
Net income by year
Bottom line
| Fiscal year | NBTX | SNY |
|---|---|---|
| FY2025 | €-24.0M | €7.8B |
| FY2024 | €-68.1M | €5.6B |
| FY2023 | €-39.7M | €5.4B |
| FY2022 | €-57.0M | €8.4B |
| FY2021 | €-47.1M | €6.2B |
| FY2020 | €-33.6M | €12.3B |
| FY2019 | €-50.9M | €2.8B |
| FY2018 | €-30.3M | €4.3B |
Advertisement
AdSense · Rectangle 336×280